First- and second-generation antisense inhibitors targeted to human c-raf kinase: In vitro and in vivo studies

Anti-Cancer Drug Design

Volumn 12, Issue 5, 1997, Pages 327-339

  Monia, Brett P ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; MITOGEN ACTIVATED PROTEIN KINASE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; DRUG MECHANISM; DRUG TARGETING; PRIORITY JOURNAL; REVIEW;

ANIMALS; BASE SEQUENCE; ENZYME INHIBITORS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; RNA, MESSENGER;

EID: 0030760355     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. ALTMANN, K-H., DEAN, N.M., FABBRO, D., FREIER, S.M., GEIGER, T., HANER, R., HUSKIN, D., MARTIN, P., MONIA, B.P., MULLER, M., NATT, F., NICKLIN, P.N., PHILLIPS, J., PIELES, V., SASMOR, H. & MOSER, H. (1996). Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia, 50, 168.
2. BACON, T.A. & WICKSTROM, E. (1991). Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5′ cap region. Oncogene Research, 6, 13.
3. BENNETT, C.F., CHIANG, H., SHOEMAKER, J.E. & MIRABELLI, C.K. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Molecular Pharmacology, 41, 1023.
4. BENNETT, C.F., DEAN, N., ECKER, D.J. & MONIA, B.P (1995). Pharmacological activity of phosphorothioate antisense oligonucleotides: in vivo studies. In Methods in Molecular Medicine: Antisense Therapeutics, Agrawal, S. (ed.). Humana Press: New York.
5. BOS, J.L (1988). The ras gene family and human carcinogenesis. Mutation Research, 195, 255.
6. BOS, J.L. (1989). ras oncogenes in human cancer: a review. Cancer Research, 49, 4682.
7. CHIANG, M.Y., CHEN, H., ZOUNES, M.A., FREIER, S.M., LIMA, W.F. & BENNETT, C.F. (1991). Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. Journal of Biological Chemistry, 266, 18162.
8. CIOFFI, C.L., GARAY, M., JOHNSTON, J.F., MCGRAW, K., BOGGS, R.T., HRENIUK, D. & MONIA, B.P. (1996). Selective inhibition of A-raf and C-raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-raf and C-raf in serum-induced proliferation. Molecular Pharmacology, in press.
9. CROOKE, S.T. (1993). Therapeutic applications of oligonucleotides. Annual Review of Pharmacology and Toxicology, 32, 329.
10. CROOKE, S T. (1996). Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Development, 6, 145.
11. CROOKE, S.T. & BENNETT, C F. (1996). Progress in antisense oligonucleotide therapeutics. Annual Review of Pharmacology and Toxicology, 36, 107.
12. DEAN, N.M., MCKAY, R., MIRAGLIA, L , HOWARD, R., COOPER, S., GIDDINGS, P., NICKLIN, P, MEISTER, L , ZEIL, R., GEIGER, T., MULLER, M. & FABBRO, D (1996). Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C alpha expression. Cancer Research, 56, 3499.
13. DE MESMAEKER, A., HANER, R., MARTIN, P & MOSER, H.E. (1995). Antisense oligonucleotides. Accounts of Chemical Research, 28, 366.
14. FREIER, S.M & TINOCO, I., JR (1975). The binding of complementary oligoribonucleotides to yeast initiator transfer RNA. Biochemistry, 14, 3310.
15. FUKUI, M., YAMAMOTO, T , KAWAI, S., MARUO, K. & TOYOSHIMA, K. (1985). Detection of a raf-related and two other transforming DNA sequences in human tumors maintained in nude mice. Proceedings of the National Academy of Sciences of the USA, 81, 5954.
16. GRAY, G D., HERNANDEZ, O.M., HEBEL, D., ROOT, M., POW-SANG, J M. & WICKSTROM, E. (1993). Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mouse. Cancer Research, 53, 577.
17. HERSCHLAG, D & CECH, T.R. (1990). Catalysis of RNA cleavage by the tetrahymena thermophila ribozyme: kinetic description of the reaction of an RNA substrate that forms a mismatch at the active site. Biochemistry, 29, 10172.
18. KASID, U., PFEIFER, A., BRENNAN, T., BECKETT, M , WEICHSELBAUM, R R , DRITSCHILO, A, & MARK, G.E (1989). Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science, 243, 1354.
19. KASID, U, SIMENG, S., DENT, P, RAY, S., WHITESIDE, T.L. & STURGILL, T.W. (1996). Activation of raf by ionizing radiation. Nature, 382, 813.
20. LIMA, W, MONIA, B.P., FREIER, S.M & ECKER, D.J. (1992). Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry, 31, 12055.
21. MILLIGAN, J.F., MATTEUCCI, M.D. & MARTIN, J.C. (1993). Current concepts in antisense drug design. Journal of Medicinal Chemistry, 36, 1923.
22. MONIA, B P., LESNIK, E., GONZALEZ, C., LIMA, W.F., GUINOSSO, C.F., KAWASAKI, A.M., COOK, R.D & FREIER, S.M. (1993). Evaluation of 2′ modified oligonucleotides containing deoxy gaps as antisense inhibitors of Ha-ras gene expression. Journal of Biological Chemistry, 268, 14514.
23. MONIA, B.P., JOHNSTON J.F, GEIGER, T., MULLER, M. & FABBRO, D. (1996a). Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature and Medicine, 2, 668.
24. MONIA, B.P., SASMOR, H., JOHNSTON, J.F., FREIER, S.M., LESNIK, E.A., MULLER, M., ALTMANN, K-H., MOSER, H. & FABBRO, D. (1996b). Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proceedings of the National Academy of Science of the USA, 93, 15481.
25. MONIA, B.P, JOHNSTON, J.F., SASMOR, H. & CUMMINS, L. (1996c). Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. Journal of Biological Chemistry, 14533.
26. MORRISON, D.K. (1995). Activation of raf-1 by ras in intact cells. Methods in Enzymology, 255, 301.
27. MULLER, M , GEIGER, T., MONIA, B.P., DEAN, N.M. & FABBRO, D. (1997). Antitumor activity of CGP 69846A and CGP 64128A in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. submitted.
28. MURRAY, J.M. & NISHIKURA, K. (1991). Application of antisense nucleic acids in oncology. In Antisense Nucleic Acids and Proteins: Fundamentals and Applications. Mol, J.N.M. & van der Krol, A.R. (eds), Humana Press: New York.
29. NECKERS, L., WHITESELL, L., ROSOLEN, A. & GESELOWITZ, D.A. (1992). Antisense inhibition of oncogene expression. In Critical Reviews in Oncogenesis. Pimentel, E. & Perucho, M. (eds), Vol. 3, p. 175. CRC Press: New York.
30. NESTEROVA, M. & CHO-CHUNG, Y. (1995). A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth. Nature and Medicine, 1, 528.
31. NISHIDA, E. & GOTOH, Y. (1993). The MAP kinase cascade is essential for diverse signal transduction pathways. Trends in Biological Sciences, 18, 128.
32. NISHIZUKA, Y. (1992). Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science, 258, 607.
33. RAPP, U.R. (1987). Role of raf oncogenes in lung carcinogenesis. In Proceedings of the International Conference on Hormones, Growth Factors and Oncogenes in Pulmonary Carcinoma. Dunbar, B.S. (ed.), p. 122. Plenum: London.
34. RAPP, U.R., CLEVELAND, J.L. & STORM, S M (1987). Oncogenes: clinical relevance. In Proceedings of Modern Trends in Leukemia vii: Hematology and Blood Transfusion. Neth, R., Gallo, R., Greaves, M.F. & Vanka, G. (eds), p. 69. Springer: Berlin.
35. REDDY, E.P., SKALKA, A.M. & CURRAN, T. (eds) (1988). The Oncogene Handbook. Elsevier Science: Amsterdam.
36. SANGHVI, Y.S & COOK, P.D (1993). Towards second-generation synthetic backbones for antisense oligonucleotides. In Nucleosides and Nucleotides as Antitumor and Antiviral Agents. Chu, C.K. & Beker, D.C. (eds), p. 311. Plenum Press: New York.
37. SCHULTE, T.W., BLAGOSKLONNY, M.V., ROMANOVA, L., MUSHINSKI, J.F., MONIA, B.P., JOHNSTON, J.F , NGUYEN, P., TREPEL, J. & NECKERS, L.M. (1996). Title? Molecular and Cellular Biology, in press.
38. SCHWAB, G., CHAVANY. C , DUROUX, L, GOUBIN, G., LEBEAU, J., HELENE, C. & SAISON-BEHMOARAS, T. (1994). Antisense oligonucleotides absorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated H-ras-mediated cell proliferation and tumorgenicity in nude mice. Proceedings of the National Academy of Science of the USA, 91, 10460.
39. SHIMIZU, K., NAKATSU, Y., SEKIGUCHI, M., HOKAMURA, K., TANAKA, K., TERADA, M. & SUGIMURA, T (1985). Molecular cloning of an activated human oncogene, homologous to V-ras, from primary stomach cancer. Proceedings of the National Academy of Sciences of the USA, 82, 5641.
40. STANTON, V.P. JR & COOPER, G.M. (1987). Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Molecular and Cellular Biology, 7, 1171.
41. STEIN, C. & KRIEG, A.M. (1994). Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Research Development, 4, 67.
42. UHLENBECK, O.C. (1972). Complementary oligonucleotide binding to transfer RNA. Journal of Molecular Biology, 65, 25.
43. UHLMANN, E. & PEYMANN, A. ((1990). Chemical Reviews, 90, 543.
44. WAGNER, R W. (1994). Gene inhibition using antisense oligodeoxynucleotides. Nature, 372, 333-335.
45. WICKSTROM, E. (ed.) (1991). Antisense DNA treatment of HL-60 promyelocytic leukemia cells: terminal differentiation and dependence on target sequence. In Prospects for Antisense Nucleic Acid Therapy of Cancer and Aids. Wiley-Liss: New York.
46. YAZAKI, T, AHMED, S., CHAHLAVI, A., ZYLBER-KATZ, E , DEAN, N.M., MARTUZA, R.L. & GLAZER, R.I (1996). Treatment of glioblastoma 0-87 by systemic administration of an antisense protein kinase C - a phosphorothioate oligodeoxynucleotide. Molecular Pharmacology, 50, 242-263.